|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | FAIR Principles:Interpretations and Implementation Considerations显示文摘The FAIR principles have been widely cited,endorsed and adopted by a broad range of stakeholders since their publication in 2016.By intention,the 15 FAIR guiding principles do not dictate specific technological implementations,but provide guidance for improving Findability,Accessibility,Interoperability and Reusability of digital resources.This has likely contributed to the broad adoption of the FAIR principles,because individual stakeholder communities can implement their own FAIR solutions.However,it has also resulted in inconsistent interpretations that carry the risk of leading to incompatible implementations.Thus,while the FAIR principles are formulated on a high level and may be interpreted and implemented in different ways,for true interoperability we need to support convergence in implementation choices that are widely accessible and(re)-usable.We introduce the concept of FAIR implementation considerations to assist accelerated global participation and convergence towards accessible,robust,widespread and consistent FAIR implementations.Any self-identified stakeholder community may either choose to reuse solutions from existing implementations,or when they spot a gap,accept the challenge to create the needed solution,which,ideally,can be used again by other communities in the future.Here,we provide interpretations and implementation considerations(choices and challenges)for each FAIR principle. | Annika Jacobsen Ricardo de Miranda Azevedo Nick Juty Dominique Batista Simon Coles Ronald Cornet Melanie Courtot Merce Crosas Michel Dumontier Chris T.Evelo Carole Goble Giancarlo Guizzardi Karsten Kryger Hansen Ali Hasnain Kristina Hettne Jaap Heringa Rob W.W.Hooft Melanie Imming Keith G.Jeffery Rajaram Kaliyaperumal Martijn GKersloot Christine R.Kirkpatrick Tobias Kuhn Ignasi Labastida Barbara Magagna PeterMcQuilton Natalie Meyers Annalisa Montesanti Mirjam van Reisen Philippe Rocca-Serra Robert Pergl Susanna-Assunta Sansone Luiz Olavo Bonino da Silva Santos Juliane Schneider George Strawn Mark Thompson Andra Waagmeester Tobias Weigel Mark D.Wilkinson Egon L.Willighagen Peter Wittenburg Marco Roos Barend Mons Erik Schultes | 2020 | Data Intelligence2020，2，1： | 26 |
| 2 | A Generic Workflow for the Data FAIRification Process显示文摘The FAIR guiding principles aim to enhance the Findability,Accessibility,Interoperability and Reusability of digital resources such as data,for both humans and machines.The process of making data FAIR(“FAIRification”)can be described in multiple steps.In this paper,we describe a generic step-by-step FAIRification workflow to be performed in a multidisciplinary team guided by FAIR data stewards.The FAIRification workflow should be applicable to any type of data and has been developed and used for“Bring Your Own Data”(BYOD)workshops,as well as for the FAIRification of e.g.,rare diseases resources.The steps are:1)identify the FAIRification objective,2)analyze data,3)analyze metadata,4)define semantic model for data(4a)and metadata(4b),5)make data(5a)and metadata(5b)linkable,6)host FAIR data,and 7)assess FAIR data.For each step we describe how the data are processed,what expertise is required,which procedures and tools can be used,and which FAIR principles they relate to. | Annika Jacobsen Rajaram Kaliyaperumal Luiz Olavo Bonino da Silva Santos Barend Mons Erik Schultes Marco Roos Mark Thompson | 2020 | Data Intelligence2020，2，1： | 5 |
| 3 | The“A”of FAIR-As Open as Possible,as Closed as Necessary显示文摘In order to provide responsible access to health data by reconciling benefits of data sharing with privacy rights and ethical and regulatory requirements,Findable,Accessible,Interoperable and Reusable(FAIR)metadata should be developed.According to the H2020 Program Guidelines on FAIR Data,data should be'as open as possible and as closed as necessary','open'in order to foster the reusability and to accelerate research,but at the same time they should be'closed'to safeguard the privacy of the subjects.Additional provisions on the protection of natural persons with regard to the processing of personal data have been endorsed by the European General Data Protection Regulation(GDPR),Reg(EU)2016/679,that came into force in May 2018.This work aims to solve accessibility problems related to the protection of personal data in the digital era and to achieve a responsible access to and responsible use of health data.We strongly suggest associating each data set with FAIR metadata describing both the type of data collected and the accessibility conditions by considering data protection obligations and ethical and regulatory requirements.Finally,an existing FAIR infrastructure component has been used as an example to explain how FAIR metadata could facilitate data sharing while ensuring protection of individuals. | Annalisa Landi Mark Thompson Viviana Giannuzzi Fedele Bonifazi Ignasi Labastida Luiz Olavo Bonino da Silva Santos Marco Roos | 2020 | Data Intelligence2020，2，1： | 4 |
| 4 | Diffusion-based tractography in neurological disorders: concepts, applications, and future developments显示文摘 | Olga Ciccarelli Marco Catani Heidi Johansen-Berg Chris Clark Alan Thompson | 2008 | Lancet Neurology2008，，8： | 1 |
| 5 | Multidetector Computed Tomography Myocardial Perfusion Imaging During Adenosine Stress显示文摘 | Richard T. George Caterina Silva Marco A.S. Cordeiro Anthony DiPaula Douglas R. Thompson William F. McCarthy Takashi Ichihara Joao A.C. Lima Albert C. Lardo | 2006 | Journal of the American College of Cardiology2006，，1： | 1 |
| 6 | Making FAIR Easy with FAIR Tools:From Creolization to Convergence显示文摘Since their publication in 2016 we have seen a rapid adoption of the FAIR principles in many scientific disciplines where the inherent value of research data and,therefore,the importance of good data management and data stewardship,is recognized.This has led to many communities asking“What is FAIR?”and“How FAIR are we currently?”,questions which were addressed respectively by a publication revisiting the principles and the emergence of FAIR metrics.However,early adopters of the FAIR principles have already run into the next question:“How can we become(more)FAIR?”This question is more difficult to answer,as the principles do not prescribe any specific standard or implementation.Moreover,there does not yet exist a mature ecosystem of tools,platforms and standards to support human and machine agents to manage,produce,publish and consume FAIR data in a user-friendly and efficient(i.e.,“easy”)way.In this paper we will show,however,that there are already many emerging examples of FAIR tools under development.This paper puts forward the position that we are likely already in a creolization phase where FAIR tools and technologies are merging and combining,before converging in a subsequent phase to solutions that make FAIR feasible in daily practice. | Mark Thompson Kees Burger Rajaram Kaliyaperumal Marco Roos Luiz Olavo Bonino da Silva Santos | 2020 | Data Intelligence2020，2，1： | 1 |
| 7 | Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation:Is the current evidence applicable to these patients?显示文摘Liver transplantation(LT)is one of the leading curative therapies for hepatocellular carcinoma(HCC).Despite recent optimization of transplant selection criteria,including alpha-feto protein,HCC recurrence after LT is still the leading cause of death in these patients.During the last decades,effective systemic treatments for HCC,including tyrosine kinase inhibitors and immunotherapy,have been approved.We describe the clinical scenario of a patient with recurrence of HCC five years after LT,who received lenvatinib as first-line systemic therapy to introduce systemic treatment options in this clinical setting.In this opinion review,we detail first and second-line systemic treatment options,focusing on those feasible for patients with recurrent HCC after LT.Several trials have evaluated new drugs to treat HCC patients in first and secondline therapy,but patients with recurrent HCC after LT have been excluded from these trials.Consequently,most of the evidence comes from observational retrospective studies.Whether tyrosine kinase inhibitors will remain the primary therapeutic approach in these patients,due to a relative contraindication for immunotherapy,may be clarified in the near future. | Federico Piñero Marcos Thompson Juan Ignacio Marín Marcelo Silva | 2020 | World Journal of Transplantation2020，10，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员